Neha Bhatia

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 6

Top Topics

Replacement Therapy

Endoplasmic Reticulum

Molecular Docking

Top Venues

Medical oncology (Northwood, London, England)

Journal of biomolecular structure & dynamics

Current medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Kulkarni Swanand Sanjay, Yogesh Singh, Avadh Biharee, Neha Bhatia, Vikram Deep Monga, Suresh Thareja
Molecular docking, 3D-QSAR and simulation studies for identifying pharmacophoric features of indole derivatives as 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5) inhibitors. Journal of biomolecular structure & dynamics (2023)
Neha Bhatia, Suresh Thareja
Elacestrant: a new FDA-approved SERD for the treatment of breast cancer. Medical oncology (Northwood, London, England) 40 (6) (2023)
Rakesh Khator, Avadh Biharee, Neha Bhatia, Kulkarni Swanand Sanjay, Yogesh Singh, Chandrabose Karthikeyan, Akhlesh Kumar Jain, Suresh Thareja
Medicinal Aspects of PTP 1B Inhibitors as Anti-Breast Cancer Agents: An Overview. Current medicinal chemistry (2023)
Kulkarni Swanand Sanjay, Yogesh Singh, Avadh Biharee, Neha Bhatia, Vikram Deep Monga, Suresh Thareja
Molecular docking, 3D-QSAR and simulation studies for identifying pharmacophoric features of indole derivatives as 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5) inhibitors. Journal of biomolecular structure & dynamics (2023)
Neha Bhatia, Suresh Thareja
Elacestrant: a new FDA-approved SERD for the treatment of breast cancer. Medical oncology (Northwood, London, England) 40 (6) (2023)
Neha Bhatia, Suresh Thareja
Elacestrant: a new FDA-approved SERD for the treatment of breast cancer. Medical oncology (Northwood, London, England) 40 (6) (2023)